

Radica Z Alicic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4999094/publications.pdf>

Version: 2024-02-01

24
papers

2,440
citations

759233

12
h-index

713466

21
g-index

26
all docs

26
docs citations

26
times ranked

3157
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An opportunity for pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, e65-e70.	1.0	5
2	Degludec hospital trial: A randomized controlled trial comparing insulin degludec <scp>U100</scp> and glargine <scp>U100</scp> for the inpatient management of patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 42-49.	4.4	12
3	KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. <i>American Journal of Kidney Diseases</i> , 2022, 79, 457-479.	1.9	18
4	Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. <i>Nature Reviews Nephrology</i> , 2021, 17, 227-244.	9.6	87
5	In Reply â€” Neutralization of Fecal Aerosol-Laden SARS CoV-2: Public Health Implications. <i>Mayo Clinic Proceedings</i> , 2021, 96, 819-820.	3.0	0
6	Glycemic Variability and KIM-1â€™Induced Inflammation in the Diabetic Kidney. <i>Diabetes</i> , 2021, 70, 1617-1619.	0.6	5
7	Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 318-327.	1.4	9
8	COVID-19 and Gastrointestinal Tract Symptoms: Recognition, Containment, and Learning From the Past. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2320-2324.	3.0	9
9	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists. <i>US Endocrinology</i> , 2020, 16, 80.	0.3	7
10	Inflammatory Mechanisms in Diabetic Kidney Disease. , 2020, , 437-455.		0
11	Sodiumâ€™Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. <i>Diabetes</i> , 2019, 68, 248-257.	0.6	80
12	Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children. <i>JAMA Network Open</i> , 2019, 2, e1918169.	5.9	130
13	Diabetic Kidney Disease. , 2019, , 42-61.e5.		1
14	Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 181-191.	1.4	91
15	SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. <i>American Journal of Kidney Diseases</i> , 2018, 72, 267-277.	1.9	102
16	Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2263-2274.	6.1	59
17	Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 2032-2045.	4.5	1,600
18	Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1467-1472.	2.3	23

#	ARTICLE	IF	CITATIONS
19	Medication Intervention for Chronic Kidney Disease Patients Transitioning from Hospital to Home: Study Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2016, 44, 122-129.	3.1	10
20	Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths. <i>Diabetes Spectrum</i> , 2015, 28, 167-174.	1.0	18
21	Novel Therapies for Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 121-133.	1.4	55
22	Direct and Indirect Effects of Obesity on the Kidney. <i>Advances in Chronic Kidney Disease</i> , 2013, 20, 121-127.	1.4	32
23	Risks of Subsequent Hospitalization and Death in Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 409-416.	4.5	78
24	Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?. <i>Current Hypertension Reports</i> , 2007, 9, 393-402.	3.5	8